原文標題：
Moderna’s mRNA Cancer Vaccine Shows Promise in Preliminary Study
原文連結：
https://on.wsj.com/3uM9xzp
發布時間：
Dec. 13, 2022 4:47 pm ET
記者署名：
Peter Loftus
原文內容：
原文節錄
A customized Moderna Inc. vaccine helped ward off the recurrence of
melanoma in a mid-stage trial, a milestone in long-running efforts
to use the shots as treatments and a big step in the biotech’s ascent.
The combination of Moderna’s personalized cancer vaccine and Merck
& Co.’s Keytruda cancer immunotherapy reduced patients's risk of
relapse or death by about 44%, versus Keytruda alone, in the 150-volunteer
study, the companies said Tuesday.
心得/評論：
一項二期臨床數據顯示莫德納的個人化疫苗搭配 Merck 的黑色素瘤免疫療法藥物
Keytruda 相對於單獨使用 Keytruda, 可降低病人在手術後的復發或死亡率達44%,
統計上為顯著。這項臨床試驗結果尚未經過正式的審查。如果證實有效，將會是
信使RNA技術在 Covid-19 疫苗後的又一項重要應用。
Moderma 的股價昨日收漲近 20%。
Moderma 和 Merck 計畫針對更多其他種類的癌症展開臨床試驗。
--
I begin again, as the world outside ends.
Dance, even in the still light, to owe you my life.
I tell you, make castles when you want to.
And fill them with sights.
Stir about the stars during nights below these tides.
--
